2010
DOI: 10.18553/jmcp.2010.16.8.605
|View full text |Cite
|
Sign up to set email alerts
|

Clinical and Economic Outcomes in Medicare Beneficiaries with Stage 3 or Stage 4 Chronic Kidney Disease and Anemia: The Role of Intravenous Iron Therapy

Abstract: • Anemia is a common occurrence in patients with chronic kidney disease (CKD), with reported prevalence rates of 9%-64% depending on CKD stage and definition of anemia and is associated with increased morbidity and mortality. In a sample of patients with incident CKD, Thorp et al. (2009) [IV]) in CKD patients with anemia (defined as hematocrit less than 33% in women of childbearing age or less than 37% in men and postmenopausal women) in whom therapy with an erythropoiesisstimulating agent (ESA) does not rai… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
8
0

Year Published

2011
2011
2021
2021

Publication Types

Select...
8

Relationship

1
7

Authors

Journals

citations
Cited by 9 publications
(8 citation statements)
references
References 27 publications
0
8
0
Order By: Relevance
“…In a recent study of Medicare beneficiaries with stage 3 or 4 CKD and anemia, anti-anemia therapy was utilized in roughly 36% of the study sample (413 out of 3,897), and the investigators found that patients not treated with IV iron had an increased cost compared with cohorts treated with IV iron. 28 Although CKD patients were excluded from the present study, findings are similar to the small percentage of postbariatric surgery patients receiving anemia management therapy, which may help to reduce costs; however, an analysis of costs between anemic patients receiving anti-anemia therapy compared with those not receiving antianemia therapy was not conducted and may be a topic for further investigation. Furthermore, the reasons for the underutilization of IV iron therapy, which may include delaying treatment until symptoms become more severe and/or concerns related to lack of benefit or side effects, are another topic of investigation in the postbariatric surgery population.…”
Section: Treatment and Tests For Anemia In Study Populationmentioning
confidence: 70%
“…In a recent study of Medicare beneficiaries with stage 3 or 4 CKD and anemia, anti-anemia therapy was utilized in roughly 36% of the study sample (413 out of 3,897), and the investigators found that patients not treated with IV iron had an increased cost compared with cohorts treated with IV iron. 28 Although CKD patients were excluded from the present study, findings are similar to the small percentage of postbariatric surgery patients receiving anemia management therapy, which may help to reduce costs; however, an analysis of costs between anemic patients receiving anti-anemia therapy compared with those not receiving antianemia therapy was not conducted and may be a topic for further investigation. Furthermore, the reasons for the underutilization of IV iron therapy, which may include delaying treatment until symptoms become more severe and/or concerns related to lack of benefit or side effects, are another topic of investigation in the postbariatric surgery population.…”
Section: Treatment and Tests For Anemia In Study Populationmentioning
confidence: 70%
“…The review was also limited in being able to obtain useful health economic data except from one recent trial [43] that demonstrated a lower cost for IV ferric carboxymaltose over IV iron sucrose, but with a higher success rate. Recent analyses also show that not treating anaemia in CKD with IV iron or ESAs led to greater mortality and cost [68]. …”
Section: Discussionmentioning
confidence: 99%
“…This kind of fine granularity of data is usually not available via larger Medicare-based populations. 3,29 There was a significant reduction in mortality only demonstrated in ESRD population, however there was a trend toward decreased mortality in CKD population who were restarted on warfarin. This was attributed to the beneficial cardiovascular effects of warfarin which are very similar to aspirin.…”
Section: Discussionmentioning
confidence: 98%